SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.

导出 OA

翻译打印收藏纠错

第一作者： Michael,Mark

第一单位： Department of Medical Oncology/Hematology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland. michael.mark@ksgr.ch.

作者： Michael,Mark ^[1] ; Patrizia,Froesch ^[2] ; Eric Innocents,Eboulet ^[3] ; Alfredo,Addeo ^[4] ; Miklos,Pless ^[5] ; Sacha I,Rothschild ^[6] ; Wolf-Dieter,Janthur ^[7] ; Henning,Burmeister ^[8] ; Alex,Friedlaender ^[4] ; Martina,Schneider ^[3] ; Yannis,Metaxas ^[9] ; Markus,Joerger ^[10] ; Luciano,Wannesson ^[2] ; Michael,Schwitter ^[9] ; Nathalie,Baudoux ^[4] ; Susanne,Weindler ^[10] ; Christine,Biaggi-Rudolf ^[3] ; Martin,Früh ^[10] ; Swiss Group for Clinical Cancer Research (SAKK) ^[11]

作者单位： Department of Medical Oncology/Hematology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland. michael.mark@ksgr.ch. ^[1] Department of Medical Oncology, EOC-Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland. ^[2] SAKK Coordinating Center, Bern, Switzerland. ^[3] Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland. ^[4] Department of Medical Oncology, Kantonsspital Winterthur, Winterthur, Switzerland. ^[5] Department of Medical Oncology, Universitätsspital Basel, Basel, Switzerland. ^[6] Department of Medical Oncology, Kantonsspital Aarau, Aargau, Switzerland. ^[7] Department of Medical Oncology, Spital STS AG Thun/Onko-Netz, Thun, Switzerland. ^[8] Department of Medical Oncology/Hematology, Kantonsspital Graubünden, Loestrasse 170, 7000, Chur, Switzerland. ^[9] Department of Medical Oncology, Kantonsspital St. Gallen, St Gallen, Switzerland. ^[10] University of Bern, Bern, Switzerland. ^[11]

关键词 Durvalumab ECOG performance status 2 Metastatic nonsmall cell lung cancer NSCLC